食管癌术中植入5氟尿嘧啶缓释剂的安全性_医学论文.docVIP

食管癌术中植入5氟尿嘧啶缓释剂的安全性_医学论文 食管癌术中植入5氟尿嘧啶缓释剂的安全性_医学论文 作者：江洪　周星明　严福来　陈奇勋【摘要】 　　［目的］探讨术中植入5?鄄氟尿嘧啶缓释剂对食管癌患者的安全性。［方法］ 82例食管癌患者行手术治疗并在术中植入缓释性5?鄄氟尿嘧啶；同时设对照组80例，予单纯手术。检测两组患者术前术后肝肾功能、白细胞、免疫指标，比较术后并发症的发生情况。［结果］ 术后两组患者肝肾功能及白细胞数值无显著性差异(P＞0.05)；术后实验组CD3+水平低于对照组(P＜0.05），其余各项免疫指标无显著性差异(P＞0.05)。实验组术后切口感染发生率为4.88%（4/82），对照组为1.25％(1/80)，P＜0.05，其余术后并发症发生率无显著性差异(P＞0.05)。结论］ 术中植入5?鄄氟尿嘧啶缓释剂治疗食管癌是比较安全的。 【关键词】 食管肿瘤　氟尿嘧啶　迟效制剂　外科学　药物疗法 　　The Safety of Implanting Sustained Release 5?鄄fluorouracil During Operation in Patients with Esophageal Cancer Abstract：［Purpose］To investigate the safety of implanting sustained release 5?鄄fluorouracil during operation for patients with esophageal cancer.［Methods］ Sustained release 5?鄄fluorouracil were implanted in 82 cases with esophageal cancer during operation. Eighty patients as control group underwent operation alone.The liver and kindney functions, WBC, immunity index were detected pre?鄄 and post?鄄operatively in the two groups,and the incidence of complications were compared.［Results］There were nosignificant differences of liver and kindney functions and WBC index between the two groups(P＞0.05).Post?鄄operative CD3+ index was lower in experimental group than that in control group(P＜0.05）. There were no significant differences of otherimmunity index between the two groups(P＞0.05). The accidence rate of infection of incisional wound in experimental group was 4.88%（4/82）,and 1.25％ in control group(1/80), P＜0.05.No significant differences of other operative complications between the two groups was found(P＞0.05).［Conclusion］Implanting sustained release 5?鄄fluorouracil during operation is safe, for esophagealcancer Key words: esophageal neoplasms fluorouracil delayed?鄄action preparations surgery drug therapy 虽然食管癌的诊断和治疗方法不断改进 ,但其预后仍然很差。到目前为止 ,外科治疗仍然是有可能延长患者生命最有效的方法[1]。但外科治疗的5年生存率仅有20 %～25 %。因此，需要不断探索新的治疗方法以辅助外科治疗。植入性缓释抗癌药治疗是肿瘤靶向治疗的方法之一。缓释性氟尿嘧啶是采用高分子聚合物将化疗药物氟尿嘧啶经过特殊工艺包裹，形成一种缓释植入剂，植入到患者体内后，杀灭植药区域及周围环境中的肿瘤细胞。其特点为既可以达到化疗的目的，对患者身体机能的影响又较小。我们从2001年3月~2002年6月随机选择了